Ken Griffin Annexon, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Annexon, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 243,700 shares of ANNX stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
243,700
Previous 169,900
43.44%
Holding current value
$1.79 Million
Previous $1.22 Million
1.97%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ANNX
# of Institutions
156Shares Held
101MCall Options Held
3.61MPut Options Held
1.08M-
Bain Capital Life Sciences Investors, LLC Boston, MA8.45MShares$62.2 Million8.47% of portfolio
-
Satter Management Co., L.P.7.41MShares$54.5 Million71.21% of portfolio
-
Bvf Inc San Francisco, CA7MShares$51.5 Million1.05% of portfolio
-
Black Rock Inc. New York, NY6.59MShares$48.5 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA6.43MShares$47.3 Million2.05% of portfolio
About Annexon, Inc.
- Ticker ANNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,617,700
- Market Cap $350M
- Description
- Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...